Wider Lens, Sharper Focus
- 19 July 2021
- journal article
- editorial
- Published by Elsevier BV in Journal of Invasive Cardiology
- Vol. 78 (4), 327-329
- https://doi.org/10.1016/j.jacc.2021.05.023
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialJournal of Invasive Cardiology, 2021
- Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelinesJournal of Vascular Surgery, 2020
- Rivaroxaban in Peripheral Artery Disease after RevascularizationThe New England Journal of Medicine, 2020
- Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical RevascularizationJournal of Invasive Cardiology, 2018
- Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)American Heart Journal, 2018
- Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudicationEmergencias, 2018
- Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent ClaudicationJAMA, 2015
- National health care costs of peripheral arterial disease in the Medicare populationVascular Medicine, 2008